Annals of Surgical Oncology

, Volume 23, Issue 2, pp 382–390 | Cite as

Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms

  • Patricio M. Polanco
  • Ying Ding
  • Jordan M. Knox
  • Lekshmi Ramalingam
  • Heather Jones
  • Melissa E. Hogg
  • Amer H. Zureikat
  • Matthew P. Holtzman
  • James Pingpank
  • Steven Ahrendt
  • Herbert J. Zeh
  • David L. Bartlett
  • Haroon A. Choudry
Colorectal Cancer



High-grade (HG) mucinous appendiceal neoplasms (MAN) have a worse prognosis than low-grade histology. Our objective was to assess the safety and efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) in patients with high-grade, high-volume (HG–HV) peritoneal metastases in whom the utility of this aggressive approach is controversial.


Prospectively collected perioperative data were compared between patients with peritoneal metastases from HG–HV MAN, defined as simplified peritoneal cancer index (SPCI) ≥12, and those with high-grade, low-volume (HG–LV; SPCI <12) disease. Kaplan–Meier curves and multivariate Cox regression models identified prognostic factors affecting oncologic outcomes.


Overall, 54 patients with HG–HV and 43 with HG–LV peritoneal metastases underwent CRS/HIPEC. The HG–HV group had longer operative time, increased blood loss/transfusion, and increased intensive care unit length of stay (p < 0.05). Incomplete macroscopic cytoreduction (CC-1/2/3) was higher in the HG–HV group compared with the HG–LV group (68.5 vs. 32.6 %; p = 0.005). Patients with HG–HV disease demonstrated worse survival than those with HG–LV disease (overall survival [OS] 17 vs. 42 m, p = 0.009; time to progression (TTP) 10 vs. 14 m, p = 0.024). However, when complete macroscopic resection (CC-0) was achieved, the OS and progression-free survival of patients with HG–HV disease were comparable with HG–LV disease (OS 56 vs. 52 m, p = 0.728; TTP 20 vs. 19 m, p = 0.393). In a multivariate Cox proportional hazard regression model, CC-0 resection was the only significant predictor of improved survival for patients with HG–HV disease.


Although patients with HG–HV peritoneal metastases from MAN have worse prognosis compared with patients with HG–LV disease, their survival is comparable when complete macroscopic cytoreduction is achieved.


Overall Survival Peritoneal Metastasis Complete Cytoreduction Residual Macroscopic Tumor Complete Macroscopic Resection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.





  1. 1.
    Austin F, Mavanur A, Sathaiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol. 2012;19:1386–93.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.PubMedCrossRefGoogle Scholar
  3. 3.
    Polanco PM, Ding Y, Knox JM, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol. 2015;22:1673–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Polanco PM, Sanchez AI, Ramalingam L, et al. Does obesity affect outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for disseminated mucinous appendiceal neoplasms? Ann Surg Oncol. 2014;21:3963–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.PubMedCrossRefGoogle Scholar
  6. 6.
    Elias D, Honore C, Ciuchendea R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95:1164–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Levine EA, Stewart JH 4th, Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–53; discussion 953–5 PubMedCrossRefGoogle Scholar
  8. 8.
    Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2005;48:1372–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Omohwo C, Nieroda CA, Studeman KD, et al. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology. J Am Coll Surg. 2009;209:308–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Stewart JH 4th, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Yan TD, Links M, Xu ZY, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93:1270–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer J. 2009;15:225–35.PubMedCrossRefGoogle Scholar
  16. 16.
    Bradley RF, Stewart JH 4th, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012;65:919–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27:1521–39.PubMedCrossRefGoogle Scholar
  19. 19.
    Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134:864–70.PubMedGoogle Scholar
  20. 20.
    Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089–103.PubMedCrossRefGoogle Scholar
  21. 21.
    Pai RK, Beck AH, Norton JA, et al. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33:1425–39.PubMedCrossRefGoogle Scholar
  22. 22.
    Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol. 2005;12:291–311.PubMedCrossRefGoogle Scholar
  23. 23.
    Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19:1390–408.PubMedCrossRefGoogle Scholar
  25. 25.
    Yantiss RK, Shia J, Klimstra DS, et al. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol. 2009;33:248–55.PubMedCrossRefGoogle Scholar
  26. 26.
    El Halabi H, Gushchin V, Francis J, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19:110–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Deraco M, Gronchi A, Mazzaferro V, et al. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. Tumori. 2002;88:370–5.PubMedGoogle Scholar
  28. 28.
    Swellengrebel HA, Zoetmulder FA, Smeenk RM, et al. Quantitative intra-operative assessment of peritoneal carcinomatosis - a comparison of three prognostic tools. Eur J Surg Oncol. 2009;35:1078–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46.PubMedCrossRefGoogle Scholar
  30. 30.
    Bao P, Bartlett D. Surgical techniques in visceral resection and peritonectomy procedures. Cancer J. 2009;15:204–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012;19:1394–1401.PubMedCrossRefGoogle Scholar
  34. 34.
    Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23:652–8.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116:316–22.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Patricio M. Polanco
    • 1
  • Ying Ding
    • 2
  • Jordan M. Knox
    • 3
  • Lekshmi Ramalingam
    • 3
  • Heather Jones
    • 3
  • Melissa E. Hogg
    • 3
  • Amer H. Zureikat
    • 3
  • Matthew P. Holtzman
    • 3
  • James Pingpank
    • 3
  • Steven Ahrendt
    • 3
  • Herbert J. Zeh
    • 3
  • David L. Bartlett
    • 3
  • Haroon A. Choudry
    • 3
  1. 1.Division of Surgical OncologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department of BiostatisticsUniversity of PittsburghPittsburghUSA
  3. 3.Division of Surgical OncologyUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations